HK1202264A1 - Polymorph compositions, methods of making, and uses thereof - Google Patents

Polymorph compositions, methods of making, and uses thereof Download PDF

Info

Publication number
HK1202264A1
HK1202264A1 HK15102813.4A HK15102813A HK1202264A1 HK 1202264 A1 HK1202264 A1 HK 1202264A1 HK 15102813 A HK15102813 A HK 15102813A HK 1202264 A1 HK1202264 A1 HK 1202264A1
Authority
HK
Hong Kong
Prior art keywords
making
methods
substantially pure
bioactive agent
brain injury
Prior art date
Application number
HK15102813.4A
Other languages
English (en)
Chinese (zh)
Inventor
Loch Macdonald R
R Davis Cara
Burton Kevin
Winchester Gary
R Stella Angela
Heshmati Parissa
Original Assignee
Edge Therapeutics, Inc.
Evonik Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edge Therapeutics, Inc., Evonik Corporation filed Critical Edge Therapeutics, Inc.
Publication of HK1202264A1 publication Critical patent/HK1202264A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102813.4A 2012-05-09 2013-05-09 Polymorph compositions, methods of making, and uses thereof HK1202264A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644523P 2012-05-09 2012-05-09
US61/644,523 2012-05-09
US13/800,480 US9399019B2 (en) 2012-05-09 2013-03-13 Polymorph compositions, methods of making, and uses thereof
US13/800,480 2013-03-13
PCT/US2013/040265 WO2013169979A2 (en) 2012-05-09 2013-05-09 Polymorph compositions, methods of making, and uses thereof

Publications (1)

Publication Number Publication Date
HK1202264A1 true HK1202264A1 (en) 2015-09-25

Family

ID=49548793

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15102813.4A HK1202264A1 (en) 2012-05-09 2013-05-09 Polymorph compositions, methods of making, and uses thereof
HK15108503.6A HK1207824A1 (en) 2012-05-09 2013-05-09 Polymorph compositions, methods of making, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15108503.6A HK1207824A1 (en) 2012-05-09 2013-05-09 Polymorph compositions, methods of making, and uses thereof

Country Status (15)

Country Link
US (2) US9399019B2 (https=)
EP (1) EP2846775A4 (https=)
JP (1) JP6338573B2 (https=)
KR (1) KR101784260B1 (https=)
CN (1) CN104955445A (https=)
AU (1) AU2013259476B2 (https=)
BR (1) BR112014027965A2 (https=)
CA (2) CA2872887C (https=)
GB (1) GB2517096A (https=)
HK (2) HK1202264A1 (https=)
IL (1) IL235262A0 (https=)
NZ (1) NZ629727A (https=)
RU (1) RU2014149362A (https=)
SG (1) SG11201407266PA (https=)
WO (1) WO2013169979A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) * 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
CN107921036A (zh) * 2015-05-29 2018-04-17 优势医疗公司 用于减少视力丧失的组合物和方法
US20190054022A1 (en) * 2016-04-07 2019-02-21 Edge Therapeutics, Inc. Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneursymal subarachnoid hemorrhage
CN105944152B (zh) * 2016-06-13 2019-02-12 龙岩紫荆创新研究院 可吸收防粘医用膜的制备方法
WO2018039039A1 (en) * 2016-08-23 2018-03-01 Edge Therapeutics, Inc. Scalable microparticulate formulations containing polymorphic nimodipine form 2 prepared by a solvent evaporation process
WO2019018306A1 (en) * 2017-07-17 2019-01-24 Edge Therapeutics, Inc. ADVANCED MICROPARTICULAR FORMULATIONS CONTAINING FORM 2 OF MICRONIZED POLYMORPHIC NIMODIPINE
CN112912066B (zh) * 2018-09-08 2022-03-29 江苏九旭药业有限公司 一种尼莫地平注射液组合物及其制备方法
US12281226B2 (en) 2018-10-04 2025-04-22 Organo Plastica Polyvinyl chloride-free lipophilic polymer based aromatized plastisol
KR102181231B1 (ko) * 2018-11-22 2020-11-20 주식회사 메디포럼제약 로티고틴 함유 고분자 미립자의 제조방법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3932645A (en) 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
DK0471036T4 (da) * 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
IT1255792B (it) 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
AU704183B2 (en) 1994-01-05 1999-04-15 Arqule, Inc. Systematic modular production of aminimide- and oxazolone-based molecules having selected properties
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
CN1304058C (zh) 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US6123956A (en) 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6869551B2 (en) * 2001-03-30 2005-03-22 Picoliter Inc. Precipitation of solid particles from droplets formed using focused acoustic energy
US20040235801A1 (en) 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
ES2427092T3 (es) * 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
US20070207211A1 (en) 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
EP1628664A4 (en) * 2003-06-04 2008-11-05 Alkermes Inc POLYMORPHIC FORMS OF NALTREXONE
JP5165240B2 (ja) 2003-07-23 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
WO2006084005A2 (en) 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
CN101045054A (zh) 2006-03-29 2007-10-03 上海医药工业研究院 尼莫地平纳米混悬剂冻干组合物、其制备方法及应用
WO2008132712A2 (en) 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
WO2008154585A1 (en) 2007-06-11 2008-12-18 Macdonald R Loch A drug delivery system for the prevention of cerebral vasospasm
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
WO2010030868A1 (en) * 2008-09-11 2010-03-18 Surmodics Pharmaceuticals, Inc. Solvent extraction microencapsulation with tunable extraction rates
JP5769626B2 (ja) 2008-09-18 2015-08-26 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 溶媒および塩を用いるマイクロカプセル封入プロセス
CN101416963A (zh) 2008-12-02 2009-04-29 沈阳万爱普利德医药科技有限公司 注射用尼莫地平冻干亚微乳剂及其制备方法
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
CA2750003A1 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
WO2010085608A1 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
CN101485632B (zh) 2009-02-11 2011-05-18 西安德天药业股份有限公司 尼莫地平脂质微球注射液及其制备方法
US20100291027A1 (en) 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
CA2784287C (en) 2009-12-22 2017-07-18 Evonik Degussa Corporation Emulsion-based process for preparing microparticles and workhead assembly for use with same
EP2538956A4 (en) 2010-02-22 2015-04-22 Edge Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING HEMORRHAGIC BRAIN DISORDERS
CA2794328C (en) 2010-03-29 2018-01-16 Evonik Degussa Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
KR20140063513A (ko) 2011-02-11 2014-05-27 에쥐 세라피틱스, 인코포레이티드 거미막밑 출혈을 갖는 인간의 예후를 개선시키기 위한 조성물 및 방법
RU2606169C2 (ru) 2011-04-05 2017-01-10 Эдж Терапьютикс Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
CN102274176B (zh) 2011-08-04 2013-11-20 上海天氏利医药科技有限公司 一种尼莫地平注射液的组合物及其制备方法与应用
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof

Also Published As

Publication number Publication date
AU2013259476A1 (en) 2014-10-30
JP2015522534A (ja) 2015-08-06
GB201418703D0 (en) 2014-12-03
US8821944B1 (en) 2014-09-02
GB2517096A (en) 2015-02-11
AU2013259476B2 (en) 2016-10-06
NZ629727A (en) 2016-06-24
IL235262A0 (en) 2014-12-31
CA2872887C (en) 2017-08-22
EP2846775A2 (en) 2015-03-18
JP6338573B2 (ja) 2018-06-06
SG11201407266PA (en) 2014-12-30
CN104955445A (zh) 2015-09-30
US9399019B2 (en) 2016-07-26
BR112014027965A2 (pt) 2017-06-27
WO2013169979A3 (en) 2015-06-18
KR101784260B1 (ko) 2017-11-06
RU2014149362A (ru) 2016-06-27
HK1207824A1 (en) 2016-02-12
CA2872887A1 (en) 2013-11-14
KR20150021517A (ko) 2015-03-02
WO2013169979A9 (en) 2015-01-08
US20130302431A1 (en) 2013-11-14
CA2961123A1 (en) 2013-11-14
WO2013169979A2 (en) 2013-11-14
EP2846775A4 (en) 2016-04-13
US20140271895A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
HK1202264A1 (en) Polymorph compositions, methods of making, and uses thereof
GB2513675A (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
HK1209021A1 (en) Nanotherapeutics for drug targeting
HK1216002A1 (zh) 治疗动脉瘤性蛛网膜下出血并发症的组合物及其用途
WO2012178089A9 (en) Trimmed-end aneurysm embolization devices
WO2012074588A3 (en) Shear controlled release for stenotic lesions and thrombolytic therapies
IN2012DN00570A (https=)
IN2014DN09805A (https=)
WO2011041462A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
HK1206577A1 (en) Fenestrated implant
MY173823A (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
IN2014DN09804A (https=)
WO2015066426A3 (en) Angiopoietin-based interventions for treating cerebral malaria
HK1204928A1 (en) Inhibitors of the notch signalling pathway and secretion for use in medicine
WO2014066799A3 (en) Modulators of resistant androgen receptor
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
WO2011157720A3 (en) Ivabradine-containing pharmaceutical composition with modified release
HK1252771A1 (zh) 用於治疗眼部病状的玻璃体内药物递送系统
BR112013002591A2 (pt) polialfaolefinas de elevada viscosidade estáveis em cisalhamento
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
WO2011147034A8 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof
WO2012063269A3 (en) Process for preparing iloperidone